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Organ	site	 	 Orthovoltage	(<1960)		 					Betatron	³1960	
	
Brain	 	 	 	 3.6	 	 	 1.6	
Eye	treated	 	 	 60	 	 	 45	
Eye	untreated	 	 18	 	 	 34	
	Nasal	region			 	 34	 	 	 3.2	
	Salivary	 	 	 4.3	 	 	 1.6	
Head	(soft	tissue)	 	 22	 	 	 11	
Facial	bones	 	 	 28	 	 	 	8	
	Thyroid	 	 	 2.0	 	 	 0.9	
	Lung	 	 	 	 0.5	 	 	 0.4	
	Breast	 	 	 0.4	 	 	 0.4	
Kidney	 	 	 0.1	 	 	 0.3	
Stomach	 	 	 0.2	 	 	 0.4	
Colon	 	 	 	 0.1	 	 	 0.2	
Bladder	 	 	 0.1	 	 	 0.2	
Uterus	 	 	 0.1	 	 	 0.2	





























































































































































































1	 Female	 Yes	 Unknown	 39	 60	pack-yrs	
2	 Female	 No	 Small	cell/large	
cell	mixed	
40	 19	pack-yrs	
3	 Female	 Yes	 Small	cell	 40	 20	pack-yrs	
4	 Female	 No	 Adenocarcinoma	 52	 Non-smoker	






























































































































No.	of	subjects	 963	(100)	 	 638	(100)	
Laterality	 	 	 	
				Unilateral	 	 47	(4.9)	 	 638	(100)	
				Bilateral	 	 916	(95.1)	 	 0	(0.0)	
Sex	 	 	 	 	
			Male	 	 512	(53.2)	 	 334	(52.3)	
			Female	 	 451	(46.8)	 	 304	(47.7)	
Age	at	Rb	diagnosis		 	 	 	
		<	1	yr	 	 545	(56.6)	 	 140	(21.9)	
					1	yr	 	 267	(27.7)	 	 197	(30.9)	
					2	yr	 	 110	(11.4)	 	 159	(24.9)	
					3—7	yrs	 	 41	(4.3)	 	 142	(22.3)	
Yr.	of	Rb	diagnosis	 	 	 	
		1914-49	 106	(11.0)	 	 75	(11.8)	
		1950-59	 	 200	(20.8)	 	 100	(15.7)	
		1960-69	 	 312	(32.4)	 	 198	(31.0)	
		1970-79	 	 253	(26.3)	 	 192	(30.1)	
		1980-84	 	 92	(9.5)	 	 73	(11.4)	
Family	history	of	Rb	 	 	 	
	Yes	 	 283	(29.3)	 	 0	(0.0)	
	No	 	 497	(51.6)	 	 499	(78.1)	
	Uncertain	 	 183	(19.1)	 	 139	(21.9)	
Treatment		 	 	 	
		Surgery	 	 95	(9.9)	 	 480	(75.2)	
	 58	
		Chemotherapy		 16	(1.6)	 	 38	(6.0)	
		Radiation	 	 466	(48.4)	 	 67	(10.5)	
		Radiat/Chemo	 383	(39.8)	 	 47	(7.4)	
		Unknown	 	 4	(0.3)	 	 6	(0.9)	
Any	Radiotherapy	 	 	 	
			Yes	 	 849	(88.2)	 	 114	(17.5)	



























No.	of	persons	 	 						963	 	 	 	 						638	 	
Person	years	at	risk	 		 	25,309	 		 		 		 	18,972	 		
	 Hereditary	 	 Non-hereditary	
Cancer	Site	(ICD-0	Classification)	 O	 E	 SIR	(95%	CI)	 	 O	 E	 SIR	(95%	CI)	
All	sites
†
	 260	 13.9	 19	(16-21)	 	 17	 13.9	 1.2	(0.7-2.0)	
Bone	(170)	 75	 0.21	 360	(283-451)	 	 0	 0.16	 0.0	(0.0-22.6)	
Connective	and	soft	tissue	(171,	192.4,	192.5)	 34	 0.28	 122	(84-170)	 	 0	 0.22	 0.0	(0.0-16.8)	
Nasal	Cavities	(160)	 32	 0.03	 1111	(760-1569)	 	 0	 0.03	 0.0	(0.0-135)	
Cutaneous	melanoma	(173	and	M872-878)	 29	 1.05	 28	(18-40)	 	 0	 1.00	 0.0	(0.0-3.7)	
Eye	and	orbit	(190)	 17	 0.06	 266	(155-426)	 	 0	 0.05	 0.0	(0.0-81)	
Brain,	CNS	(191-192.0-.3,192.9)	 10	 0.74	 13.6	(6.5-25)	 	 2	 0.58	 3.43	(0.4-12)	
Female	Breast	(174)	 10	 2.52	 3.96		(1.9-7.3)	 	 7	 2.46	 2.84	(1.1-5.9)	
Corpus	uteri	(182)	 7	 0.35	 20	(8.0-41)	 	 0	 0.35	 0.0	(0.0-10)	
Buccal	cavity	(140-149)‡	 7	 0.34	 20	(8.2-42)	 	 0	 0.37	 0.0	(0.0-9.9)	
Lung	(162)	 5	 0.84	 5.94	(1.9-14)	 	 0	 1.11	 0.0	(0.0-3.3)	
Pineoblastoma	(194.4)	 5	 0.06	 90.8	(29-212)	 	 0	 0.04	 0.0	(0.0-93)	
Colon	(153)	 3	 0.48	 6.28	(1.3-18)	 	 0	 0.58	 0.0	(0.0-6.3)	
Hodgkin	lymphoma	(M9650-67)	 3	 0.88	 3.4	(0.7-10)	 	 1	 0.70	 1.4	(0.04-8.0)	
Bladder	(188,	189.9)	 2	 0.32	 6.15	(0.7-22)	 	 0	 0.41	 0.0	(0.0-8.8)	
Leukemia	(204-207)	 2	 0.89	 2.25	(0.3-8.1)	 	 1	 0.66	 1.47	(0.04-8.2)	
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849 658 529 339 112 19
No Radiotherapy
114 102 86 62 35 11




(95% CI = 32.6%-43.8%)
21.0%
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Hereditary              
963 760 615 401 147 30
Non-Hereditary      
638 570 500 317 13 46
Number of Patients at Risk
36.0%
95% CI = (30.8% – 41.1%)
5.69%

































































































































































































































































	 1	-	9	yrs	 10	-	19	yrs	 20	-	29	yrs	 30+	yrs	
No.	of	subjects	starting	each	
interval	 963	 791	 658		 465		
No.	of	person-years	 7649	 7381	 5691	 4573	
Histology	and	ICD-O	Classification	 O
	
*	 SIR,	95%CI†	 	 O	 SIR,	95%CI	 O	 	
SIR,	
95%CI	 O	 	 SIR,	95%CI	 	
Soft	tissue	tumors	and	sarcomas,	
NOS		 4	 229	(62-585)	 2	 85	(9.5-307)	 1	 34	(0.4-192)	 3	 88	(18-258)	
Fibrosarcoma		 4	
598	(161-
1531)	 4	 387	(104-904)	 2	 250	(28-904)	 3	 393	(79-1147)	
Malignant	Fibrous	Histiocytoma		 2	 488	(55-1760)	 4	 209	(56-534)	 1	 24	(0.3-136)	 5	 90	(29-210)	
Liposarcoma		 0	 0	(0-5038)	 2	 836	(94-3019)	 0	 0	(0-467)	 1	 51	(0.7-282)	





Rhabdomyosarcoma		 4	 340	(92-871)	 3	 286	(57-835)	 0	 0	(0.0-908)	 1	 428	(5.6-2380)	
Total	 14	 335	(183-562)	 16	 227	(129-368)	 8	 79	(34-155)	
3
1	 193	(131-274)	



































































































































		 All	 Hereditary	 Nonhereditary	
No.	of	persons	followed	up	 1854	 1092	 762	
Person-years	 49924	 28250	 21674	
Cause	of	Death*	(ICD-8	code)	 O	 SMR	(95%	CI)	 EAR	 O	 SMR	(95%	CI)	 EAR	 O	 SMR	(95%	CI)	 EAR	
Malignant	and	benign	neoplasms	other	
than	Rb†	
172	 19	(16,	22)	 32.6	 160	 37	(31,	43)	 55.1	 12	 2.5	(1.3,	4.3)	 3.3	
Malignant	neoplasms	other	than	Rb	 163	 18	(15,	21)	 30.8	 151	 35	(30,	41)	 51.9	 12	 2.5	(1.3,	4.4)	 3.3	
Bone	(170)	 56	 332	(251,	431)	 11.2	 56	 595	(449,	773)	 19.8	 0	 0	(0,	49)	 0.0	
Connective	tissue	(171)	 31	 175	(119,	248)	 6.2	 31	 329	(223,	467)	 10.9	 0	 0	(0,	44)	 0.0	
Melanoma	(172)	 13	 44	(24,	76)	 2.5	 13	 89	(47,	151)	 4.5	 0	 0	(0,	25)	 -0.1	
Brain	and	other	parts	of	nervous	system	
(191-192)	
12	 16	(8.4,	28)	 2.3	 10	 25	(12,	46)	 3.4	 2	 5.9	(0.7,	21)	 0.8	
Brain	(191)	 8	 13	(5.5,	25)	 1.5	 6	 18	(6.5,	39)	 2.0	 2	 6.7	(0.8,	24)	 0.8	
Other	parts	of	nervous	system	(192)
‡
	 4	 36	(9.6,	91)	 0.8	 4	 61	(16,	155)	 1.4	 0	 0	(0,	80)	 0.0	
Lung	and	trachea	(162)	 8	 4.9	(2.1,	9.7)	 1.3	 8	 12	(5.3,	24)	 2.6	 0	 0	(0,	3.8)	 -0.5	
Corpus	uteri	(182)§	 6	 81	(30,	177)	 1.2	 5	 154	(50,	359)	 1.8	 1	 24	(0.3,	134)	 0.4	
Nasal	cavities	(160)	 5	 392	(126,	914)	 1.0	 5	 790	(254,	
1843)	
1.8	 0	 0	(0,	570)	 0.0	
Breast	(174)	 5	 5.1	(1.6,	12)	 0.8	 2	 4.4	(0.5,	16)	 0.5	 3	 5.7	(1.2,	17)	 1.1	
Buccal	cavity	and	pharynx	(140-149)**	 2	 15	(1.7,	55)	 0.4	 2	 34	(3.8,	123)	 0.7	 0	 0	(0,	51)	 -0.03	
Leukemia	(204-207)
††
	 2	 1.9	(0.2,	6.9)	 0.2	 1	 1.7	(0.02,	9.5)	 0.1	 1	 2.2	(0.03,	12)	 0.2	
Thyroid	(193)	 1	 55	(0.7,	305)	 0.2	 0	 0	(0,	436)	 0.0	 1	 102	(1.3,	568)	 0.5	
Bladder	(188)	 1	 15	(0.2,	85)	 0.2	 1	 40	(0.5,	224)	 0.3	 0	 0	(0,	90)	 0.0	
Benign	tumors	(210-239)
‡‡








	 All	 Hereditary	 Nonhereditary	
No.	of	persons	followed	up	 1854	 1092	 762	










































































































































































Risk	factor	 O	 RR	(95%CI)	 P*	 O	 RR	(95%	CI)	 P*	
Radiation	 	 	 0.001	 	 	 0.002	
No	 11	 1.0	(referent)	 	 6	 1.0	(referent)	 	
Yes	 140	 2.46	(1.39,	4.84)	 	 6	 7.19	(2.21,	23.37)	 	
Sex	 	 	 0.03	 	 	 0.42	
Male	 67	 1.0	(referent)	 	 4	 1.0	(referent)	 	
Female	 84	 1.41	(1.03,	1.95)	 	 8	 1.63	(0.51,	6.21)	 	
Age	at	Rb	diagnosis	 	 	 0.06	 	 	 0.63	
0-12	months	 95	 1.37	(0.99,	1.93)	 	 3	 1.40	(0.31,	4.79)	 	
>12	months	 56	 1.0	(referent)	 	 9	 1.0	(referent)	 	
Calendar	year	of	RB	diagnosis	 0.05	 	 0.10	
1914-1959	 78	 1.44	(1.00,	2.05)	 	 9	 3.85	(0.77,	21.02)	 	
1960+	 73	 1.0	(referent)	 	 3	 1.0	(referent)	 	
Latency,	years	 	 	 <0.001	 	 	 0.05	
1-9	 19	 1.0	(referent)	 	 1	 1.0	(referent)	 	
10-19	 52	 3.40	(2.05,	5.90)	 	 3	 3.28	(0.41,	66.62)	 	
20-29	 25	 2.01	(0.91,	4.22)	 	 2	 0.94	(0.02,	40.50)	 	
30-39	 30	 3.59	(1.33,	9.56)	 	 0	 NA	 	
40+	 25	 5.82	(2.09,	15.95)	 	 6	 2.79	(0.07,	170.38)	 	
Attained	age	 	 	 0.76	 	 	 0.37	
1-24	years	 81	 1.0	(referent)	 	 4	 1.0	(referent)	 	













































































































































1	 Yes	 Yes	 199	(10.7)	
2	 Yes	 No	or	unknown	 837	(45.2)	
3	 No	 Yes	 36	(2.0)	









































Characteristic	 No.	 %	 No.	 %	 No.	 %	 No.	 %	
No.		Survivors	 199	 10.7	 837	 45.2	 36	 1.9	 780	 42.1	
Sex	 	 	 	 	 	 	 	 	 	
Male	 	 107	 53.8	 434	 51.8	 20	 55.6	 395	 50.6	
Female	 	 92	 46.2	 403	 48.2	 16	 44.4	 385	 49.4	
	 	 	 	 	 P=0.626	 	 	 	 P=0.564	
Age	at	Rb	 	 	 	 	 	 	 	 	 	
<12	months	 	 153	 76.9	 454	 54.2	 19	 52.8	 173	 22.2	
12-23	months	 	 29	 14.6	 251	 30.0	 10	 27.8	 224	 28.7	
24+	months	 	 17	 8.5	 132	 15.8	 7	 19.4	 383	 49.1	
	 	 	 	 	 P<0.001	 	 	 	 P<0.001	
Calendar	yr	RB	 	 	 	 	 	 	 	 	
<1960	 	 45	 22.6	 252	 30.1	 5	 13.9	 178	 22.8	
1960-69	 	 48	 24.1	 245	 29.3	 8	 22.2	 205	 26.3	
1970-79	 	 45	 22.6	 195	 23.3	 12	 33.3	 196	 25.1	
1980+	 	 61	 30.7		 145	 17.3	 11	 30.6	 201	 25.8	
Median	year	 	 1970	 1966	 1975	 1970	
	 	 	 	 	 P<0.001	 	 	 	 P=0.448	
Radiation	 	 	 	 	 	 	 	 	 	
Yes	 	 184	 92.5	 747	 89.3	 20	 55.6	 138	 17.7	
No	 	 14	 7.0	 87	 10.4	 16	 44.4	 635	 81.4	
Unknown	 	 1	 0.5	 3	 0.3	 0	 0	 7	 0.9	
	 	 	 	 	 P=0.344	 	 	 	 P<0.001	
Chemotherapy	 	 	 	 	 	 	 	 	
Yes	 	 72	 36.2	 349	 41.7	 5	 13.9	 101	 12.9	
No	 	 123	 61.8	 474	 56.6	 31	 86.1	 669	 85.8	
Unknown	 	 4	 2.0	 14	 1.7	 0	 0	 10	 1.3	
	 	 	 	 	 P=0.334	 	 	 	 P=0.784	
Attained	age	 	 	 	 	 	 	 	 	
<10	years	 	 47	 23.6	 183	 21.9	 3	 8.3	 113	 14.5	
10-19	years	 	 55	 27.6	 139	 16.6	 5	 13.9	 101	 12.9	
20-29	years	 	 29	 14.6	 136	 16.2	 13	 36.1	 169	 21.7	
30-39	years	 	 46	 23.1	 224	 26.8	 11	 30.6	 186	 28.9	
40+	years	 	 22	 11.1	 155	 18.5	 4	 11.1	 211	 27.0	
	 	 	 	 	 P=0.002	 	 	 	 P=0.077	
Median	follow	up	yrs	



















Retinoblastoma	 	 Bilateral	 Unilateral	 	
		 		 		 Family	history	 No	family	history*	 Family	history	 No	family	history*	 		
No.	survivors	 	 199	 837	 36	 780	 	











Exp	 1.6	 10.1	 0.4	 14.5	 	
SIR	 35.8	 19	 7.1	 1.52	 	
95%CI	 (27-46)	 (16-22)	 (1.5-21)	 (0.9-2.3)	 	
AER	 133	 90	 29	 3.7	 	
Bone	(170)	 O	 15	 62	 0	 0	 	
	
Exp	 0.03	 0.16	 0.01	 0.17	 	
SIR	 459	 388	 0	 0	 	
95%CI	 (259-757)	 (297-497)	 (0-460)	 (0-21)	 	
AER	 37	 35	 -0.09	 -0.08	 	
Soft	tissue		(171,	192.4-.5)	
O	 10	 25	 1	 0	 	
Exp	 0.04	 0.21	 0.01	 0.23	 	
SIR	 233	 118	 106	 0	 	
95%CI	 (112-428)	 (76-174)	 (2.7-594)	 (0.0-16)	 	
AER	 24	 13	 11	 -0.11	 	
Cutaneous	Melanoma	
(173,	M8720-8790)	
O	 8	 15	 1	 0	 	
Exp	 0.12	 0.77	 0.03	 0.99	 	
SIR	 65.5	 19.6	 35	 0	 	
95%CI	 (29-129)	 (11-32)	 (0.9	-193)	 (0-3.6)	 	
AER	 19	 7.2	 6.3	 -0.5	 	
Eye/orbit		
(190)	
O	 2	 8	 0	 0	 	
Exp	 0.01	 0.05	 0	 0.05	 	
SIR	 177	 155	 0	 0	 	
95%CI	 (21-640)	 (67-305)	 (0->1000)	 (0-73)	 	
AER	 4.9	 4.0	 -0.02	 -0.02	 	
Nasal	cavities	(160)	 O	 7	 22	 0	 0	 	
Exp	 0.01	 0.02	 0	 0.03	 	
SIR	 2000	 1041	 0	 0	 	
95%CI	 (803->1000)	 (652->1000)	 (0->1000)	 (0-132)	 	




O	 2	 9	 0	 2	 	
Exp	 0.12	 0.57	 0.03	 0.63		 	
SIR	 16.7	 15.7	 0.0	 3.2		 	
95%CI	 (2.0-60)	 (7.2-30)	 (0-146)	 (0.4-11)	 	




Pineoblastoma	 O	 6	 2	 0	 0	 	
(194.4)	 Exp	 0.01	 0.04	 0.0	 0.04	 	
	 SIR	 584	 44.5	 0.0	 0.0	 	
	 95%CI	 (214->1000)	 (5.4-161)	 (0->1000)	 (0-82)	 	




































































Risk	Factor	 Bone	 STS	 Melanoma	
	 RR	95%CI	 RR	95%CI	 RR	95%CI	
Family	History	RB	(yes/no)	 0.92(0.5-1.6)*	 0.99	(0.5-1.9)	 3.08		(1.2-7.2)	
Age	at	RB	(≥24	months)	 0.71	(0.3-1.4)	 0.19	(0.03-0.6)	 0.45(0.1-1.6)	
Calendar	Yr	RB	(<1970)	 0.93	(0.6-1.6)	 0.87	(0.4-1.8)	 5.99	(1.2-110)	
Sex	(Female)	 0.92	(0.6-1.5)	 0.76	(0.5-1.3)	 1.92	(0.8-4.7)	
Radiotherapy	(yes/no)	 7.05	(1.6-125)	 7.16	(1.6-127)	 1.46	(0.4-9.3)	
Chemotherapy	(yes/no)	 1.71	(1.1-2.8)	 1.32	(0.8-2.2)	 0.83	(0.4-2.0)	











































































































































cancer	 25	years	 50	years	 25	years	 50	years	 P	
Bone		 8.4	(5.2-11.6)	 13.0	(2.1-23.9)	 11.7	(7.4-16.0)	 14.7	(3.9-25.5)	 0.16	
Leiomyosarcoma	 0.5	(0.0-1.3)	 6.3	(0.0-14.3)	 0.7	(0.0-1.8)	 8.7	(0.0-17.4)	 0.02	
Other/unspecified	
soft	tissue	sarcoma	
4.8	(2.3-7.3)	 15.5	(3.5-27.5)	 3.3	(0.9-5.7)	 9.2	(0.4-18.0)	 0.35	



















































































































































































































































--	 --	 +++	 NE	 NE	
Age	at	RB	 --	 ++	 --	 NE	 NE	
Calendar	Yr	RB	 --	 --	 ++	 NE	 NE	
Sex	 --	 --	 --	 +++	 ++	
Radiotherapy	
(yes/no)	
+++	 +++	 --	 +	 --	
Chemotherapy	
(yes/no)	
+++	 ++	 --	 +	 NE	
Older	Attained	
Age	(>25	yrs)	
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